SAMe (S-adenosyl-L-methionine)

SAMe (S-Adenosyl-L-Methionine): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Nomenclature

S-Adenosyl-L-methionine is also called S-adenosyl methionine, S-adenosylmethionine, SAMe, or SAM-e in the United States, or ademetionine in Europe, and is also frequently abbreviated as SAM and AdoMet. The IUPAC systematic name is (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate. In clinical and biochemical literature, the terms AdoMet and SAM are used interchangeably with SAMe.

Chemical Nature and Structure

S-Adenosyl methionine is a common cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation. SAMe is a simple molecule, present in all living cells and synthesized in just one step by the coupling of L-methionine with the adenosyl moiety of adenosine triphosphate (ATP). The sulfonium functional group present in S-adenosyl methionine is the center of its peculiar reactivity.

By "SAMe," it is intended to indicate both the racemic mixture and the single diastereoisomers (RS)-(+)-S-adenosyl-L-methionine and (SS)-(+)-S-adenosyl-L-methionine, also in mixtures different from the racemic mixture. SAMe is extremely unstable at temperatures above 0°C or in the presence of moisture, both as degradation of the active ingredient and as transformation of active (SS)-(+)-S-adenosyl-L-methionine into inactive (RS)-(+)-S-adenosyl-L-methionine (racemization of the substance).

Natural Source and Endogenous Occurrence

SAMe, a metabolite present in all living cells, plays a central role in cellular biochemistry as a precursor to methylation, aminopropylation, and transsulfuration pathways. SAMe is a derivative of methionine and a cofactor for multiple synthetic pathways, particularly as a methyl group donor. It is produced naturally in the body, mainly by the liver, and is manufactured synthetically in supplement form.

AdoMet is the principal biological methyl donor made in the cytosol of every mammalian cell, but the liver is where the bulk of AdoMet is generated, as it is the site where up to half of the daily intake of methionine is metabolized and up to 85% of all methylation reactions takes place. The main natural source of SAMe for human beings is through intake of food with high protein content of its methionine precursor. It is calculated that a person under a normal-protein diet averagely ingests about 1 gram of methionine to be converted into SAMe per day. The half-life of SAMe in the liver is very short (about 5 minutes), which demonstrates the avidity of the organ for this molecule.

While the body generally produces sufficient SAMe, deficiencies in certain nutrients like methionine, folate, or vitamin B12 can lower its levels. As it is not abundant in food sources, supplementation is necessary for those looking to increase their SAMe intake.

Commercial Forms and Preparations

SAMe supplementation was initially considered impractical, due to the instability of the SAMe ion during manufacturing, shipping, and storage. Eventually, stable salts of SAMe were developed, such as SAMe tosylate disulfate, the butanedisulfonate salt of SAMe, the di-para-toluene sulfonate disulfate of SAMe, and the tri-para-toluene sulfonic acid salt of SAMe.

It was only after the second half of the 1970s that supplementation was put into practice with the introduction into the pharmaceutical market of the first preparations, administered parenterally (both intravenous and intramuscular) or orally (swallowable, either gastro-protected or gastro-resistant tablets) of salts of SAMe. SAMe can be taken orally, through a muscular injection, or by IV.

SAMe is sold in the United States as a dietary supplement. In some countries in Europe, SAMe is a prescription drug. It has been in use for decades in Europe and is a prescription medication in such countries as Italy, Spain, Germany, and Russia. S-adenosyl-l-methionine (AdoMet or SAM-e) has been available as a dietary supplement in the United States since 1999.

2. Historical Discovery and Early Research

Unlike most botanical dietary supplements, SAMe has no ancient traditional use as a botanical preparation. Its history is entirely rooted in twentieth-century biochemical research rather than folk or herbal medicine.

Giulio Cantoni discovered AdoMet in 1953. He elegantly demonstrated that methionine and ATP reacted to form a molecule, and after determination of its chemical structure, he named it AdoMet, capable of transferring a methyl group to nicotinamide or guanidinoacetic acid to form N-methylnicotinamide and creatine, respectively. The chemical structure of SAMe was described as early as 1952 (Cantoni GL. "The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate." J Am Chem Soc 1952; 74:2942-2943).

Giulio Cantoni, M.D., was the founding chief of one of the National Institute of Mental Health's laboratories. He pioneered understanding of methylation, a key chemical reaction increasingly appreciated as the switch that turns genes on and off in biological processes ranging from cancer metastasis to nurture's influence on nature in shaping stress reactivity.

SAMe has been studied extensively since its chemical structure was first described in 1952. Decades of research on the biochemical and molecular roles of SAMe in cellular metabolism have provided an extensive foundation for its use in clinical studies, including those on depression, dementia, vacuolar myelopathy, liver disease, and osteoarthritis.

After being first used in Italy, the use of SAMe in the pharmaceutical industry spread into other countries such as Spain, Germany, Russia, and China in the 1980s–1990s. Starting from 1999, SAMe, salified with tosylate or butanedisulfonate, was introduced in the USA as a food supplement in the form of gastro-protected swallowable tablets.

3. Key Biochemical Pathways and Mechanisms of Action

Overview

SAMe is an essential factor in three major biochemical pathways (most important in the liver): transmethylation, transsulfuration, and aminopropylation. SAMe functions as a donor of methyl groups and is thus essential for the activation or elimination of many substances.

Transmethylation

In transmethylation, AdoMet donates its methyl group to a large variety of acceptor molecules in reactions catalyzed by methyltransferases (MTs). Over 200 proteins in the human genome have been identified as known or putative AdoMet-dependent MTs. These enzymes transfer a methyl group from AdoMet to a variety of nucleophiles, including oxygen, sulfur, nitrogen, and carbon atoms on proteins, nucleic acids, carbohydrates, lipids, and small molecules. The substrates to which SAMe is able to transfer its methyl group include DNA, RNA, proteins, small molecules, or lipids, depending on the specific methyltransferase involved in the reaction.

SAMe donates its methyl group to a large variety of acceptor molecules in reactions catalyzed by methyltransferases, generating S-adenosylhomocysteine (SAH), which is in turn hydrolyzed to homocysteine (Hcy) and adenosine through a reversible reaction. SAH is a potent competitive inhibitor of methylation reactions, so that prompt removal of Hcy and adenosine is required to prevent SAH accumulation.

Transsulfuration and Glutathione Synthesis

For transsulfuration, SAMe generates sulfur-containing compounds, which are important for conjugation reactions and for synthesis of glutathione (GSH). In hepatocytes, homocysteine can be remethylated to generate methionine by methionine synthase, which requires normal levels of folate and vitamin B12. Hcy can also be converted to cysteine via the transsulfuration pathway by a two-enzyme process: first, Hcy condenses with serine to form cystathionine in a reaction catalyzed by cystathionine β-synthase, which requires vitamin B6. The second step cleaves cystathionine, releasing free cysteine for GSH synthesis.

Aminopropylation and Polyamine Synthesis

SAMe constitutes the first product of the "methionine cycle" that interacts with the polyamine synthesis, the transsulfuration pathway, and the folate cycle, in addition to participating in a wide variety of transmethylation reactions. SAMe is involved in epigenetics and biosynthesis of phosphatidylcholine, creatinine, and polyamine.

Regulation of SAMe Synthesis

Although sharing an amino acid identity of 84%, MAT II has the lowest Km for methionine (4–10 μM), whereas MAT III has the highest Km (215 μM–7 mM), and MAT I shows an intermediate Km (23 μM–1 mM). This enzymatic diversity allows the cell to precisely regulate SAMe synthesis under variable physiological conditions, from SAMe production at low methionine levels by MAT II to the handling of very high methionine concentrations by MAT III, even avoiding possible toxicity.

Relationship Between SAMe and the Nervous System

There has been an interesting report that a particular polymorphism of methylenetetrahydrofolate reductase, the enzyme that activates the methyl group of tetrahydrofolate used in resynthesizing S-adenosylmethionine, is overrepresented in patients with late-onset forms of major depression. Thus, there is evidence that deficiency of SAMe may cause or exacerbate depression. It is not entirely clear how SAMe produces its antidepressant effect. In view of the relationship between SAMe, folate, and B12, as well as the fact that folate and B12 deficiencies are relatively common in major depression, it is possible that SAMe indirectly treats depression by relieving symptoms that are metabolically downstream from folate and B12 deficiency. It has been suggested that SAMe might improve mood by enhancing dopamine synthesis.

Concentrations of the polyamines in the brain decrease in animal models of depression and are restored by therapeutic doses of SAMe. Intraperitoneal and intracerebroventricular administrations of putrescine have antidepressant effects in the forced swimming and tail-suspension models of depression, and this is thought to be mediated by polyamine activity at central NMDA receptors. It seems possible that SAMe produces antidepressant effects by several different mechanisms.

4. Scientific Evidence by Area of Use

4.1 Depression and Mood Disorders

Background

SAMe, a naturally occurring body chemical available as a dietary supplement, was discovered in the 1950s. SAMe deficiency is associated with depression. The antidepressant potential of SAMe has been investigated in clinical trials since the 1970s.

Clinical Evidence

A 2024 systematic review and meta-analysis categorized 23 trials (N = 2,234) into 11 trials comparing SAMe vs. placebo, 5 trials comparing SAMe + antidepressant vs. placebo + antidepressants, and 7 trials comparing SAMe vs. antidepressants. SAMe demonstrated a significantly greater reduction in depressive symptoms compared to placebo (SMD = −0.58, 95% CI [−0.93; −0.23], I² = 68%).

A 2020 clinician-oriented systematic review also examined this body of evidence: Eight trials, with a total of 11 arms and 1,011 subjects evaluating the efficacy of SAMe used as monotherapy or as adjunctive therapy (512 individuals), were included. The study duration ranged between 2 and 12 weeks and the daily dose of SAMe varied from 200 to 3,200 mg. Five comparisons evaluated the differences between SAMe and placebo, and SAMe resulted significantly better than placebo in three of these studies. Four comparisons evaluated the differences between SAMe and other antidepressants (imipramine or escitalopram) and showed no significant difference. One study showed that SAMe was significantly better than placebo in accelerating the response to imipramine from day 4 to day 12, but mean scores were not statistically different at the day-14 endpoint. One study showed that SAMe combined with serotonin reuptake inhibitors (SSRIs) was better than placebo combined with SSRI.

The existing trials of SAMe, used as monotherapy or as add-on to another antidepressant, have shown encouraging and generally positive results. However, more evidence is necessary before definitive conclusions can be drawn.

Evidence Strength

While research has shown that SAMe has a positive effect in treating depression, most studies weren't well designed and included a small number of people. Of the 38 interventions reviewed in one systematic review, the ones with the best evidence of efficacy in depressive disorders were S-adenosylmethionine, St John's wort, bibliotherapy, computerised interventions, distraction, relaxation training, exercise, pleasant activities, sleep deprivation, and light therapy. Overall, evidence is promising but not definitive: effect sizes are moderate, heterogeneity is high across trials, and sample sizes have generally been small.

4.2 Osteoarthritis

Background and Proposed Mechanism

SAMe has been studied for osteoarthritis (OA) since the 1980s on the basis of its ability to support cartilage metabolism and exert anti-inflammatory effects. In vitro research has examined SAMe's potential to support proteoglycan and fibronectin synthesis in synovial cells and chondrocytes.

Clinical Evidence

Osteoarthritis is the most common form of joint disease and the leading cause of pain and disability in the elderly. S-Adenosylmethionine may be a viable treatment option, but the evidence about its effectiveness and safety is equivocal.

One important clinical trial examined long-term use: patients received 600 mg of SAMe daily for the first two weeks and thereafter 400 mg daily until the end of the 24th month of treatment. At the end of the 24-month observation period, 97 of the patients were still in the study. SAMe administration showed good clinical effectiveness and was well tolerated. The improvement of the clinical symptoms during therapy with SAMe was already evident after the first weeks of treatment and continued up to the end of the 24th month.

A double-blind crossover trial compared SAMe directly to a COX-2 inhibitor: the study compared the effectiveness of 1,200 mg SAMe (600 mg twice daily) with 200 mg celecoxib (Celebrex 100 mg twice daily) to reduce pain and improve functional symptoms associated with OA of the knee. Each phase of the study was for a total of 8 weeks with a one-week washout between the two phases. On most health measures, both treatment groups showed significant improvements from baseline. No statistically significant difference was seen between SAMe and celecoxib. Thus, the evidence of comparable efficacy between SAMe and celecoxib seems rather solid.

Cochrane Review Findings

The Cochrane systematic review on this topic is inconclusive, hampered by the inclusion of mainly small trials of questionable quality. The effects of SAMe on both pain and function may be potentially clinically relevant and, although effects are expected to be small, deserve further clinical evaluation in adequately sized randomised, parallel-group trials in patients with knee or hip osteoarthritis. Meanwhile, routine use of SAMe should not be advised.

The Cochrane review concludes that in people with osteoarthritis, it is uncertain whether S-Adenosylmethionine affects pain or the ability to use the knee because of the low to moderate quality of the evidence.

Evidence Strength

Evidence is preliminary to moderate. Head-to-head comparisons with NSAIDs have shown numerical equivalence in some measures, but the Cochrane review cautions that the underlying trial quality is generally low, limiting firm conclusions.

4.3 Liver Diseases

Background

Given SAMe's central role in hepatic methionine metabolism, liver disease has been a primary research focus. SAMe has been studied for other liver diseases including alcoholic liver cirrhosis, hepatitis C, various types of cholestasis, and nonalcoholic steatohepatitis, as well as for the prevention of liver cancer, but research is inconclusive.

Cholestasis and Chronic Liver Disease

Over two-thirds of participants in one field trial reported substantial improvements in subjective symptoms of pruritus and fatigue using a visual analogue scale, and reductions in serum markers of cholestasis were also observed. However, although these studies provide supportive evidence for the use of SAMe in chronic liver disease, the study cohorts were poorly defined and the methodology was not to current standards for clinical trials. This is particularly so for some studies, which were not randomised and had no control arm, making it difficult to confidently draw conclusions that influence practice.

In a placebo-controlled study of hospitalised patients with cholestatic liver disease, SAMe treatment decreased abnormal liver test results and improved fatigue and mood. Clinical practice evaluation of SAMe at an oral dose of 400 mg increased to a maximum of 1,600 mg daily has suggested benefit for fatigue in a number of chronic liver diseases.

Intrahepatic Cholestasis of Pregnancy (ICP)

SAMe has also been studied in the specific context of intrahepatic cholestasis of pregnancy. Other experimental agents including S-adenosylmethionine (SAMe), cholestyramine, guar gum, and active charcoal have been studied with inconsistent results and are not routinely recommended. Randomized comparisons of SAMe vs. ursodeoxycholic acid (UDCA) in ICP have been conducted; evidence suggests UDCA is generally preferred in this indication.

Evidence Strength

Evidence for liver disease is mixed and generally preliminary. Mechanistic rationale is strong, as SAMe levels are known to be reduced in chronic liver disease, but adequately powered randomized controlled trials with clinically meaningful endpoints are lacking.

4.4 Fibromyalgia

AdoMet has been studied for use in the treatment of fibromyalgia and SAMe has also been studied for fibromyalgia, migraine, schizophrenia, Alzheimer's disease, and attention-deficit hyperactivity disorder, but there isn't enough evidence to reach conclusions about its effects in these conditions.

Evidence in fibromyalgia is preliminary. Small randomized trials have examined oral and parenteral SAMe, reporting improvements in pain, fatigue, and mood, but the trials are few and methodologically limited.

4.5 Other Investigated Areas

AdoMet has been studied for use in neurologic disorders. Research has examined its potential role in conditions including Alzheimer's disease and cognitive function, based on SAMe's role in methylation reactions important for neurotransmitter synthesis and myelin maintenance. A trial of SAMe as a quit-smoking aid showed that it didn't increase the quit rate or reduce withdrawal symptoms.

Dysregulation of SAMe metabolism is linked to various cancers, where its depletion leads to genomic instability, abnormal gene expression, and tumor progression. Studies suggest SAMe could be a useful cancer biomarker and may enhance treatment by restoring methylation balance, reducing oxidative damage, and protecting cells from chemotherapy effects. However, clinical applications remain challenging due to variability in response, poor bioavailability, and the complexity of SAMe's effects across different cancer types. This area remains investigational.

5. Body Systems Associated with SAMe

• Nervous System / Psychiatry: Antidepressant effects; role in neurotransmitter methylation and polyamine regulation in the brain.
• Musculoskeletal System: Cartilage and synovial cell support; pain modulation in osteoarthritis.
• Hepatic / Gastrointestinal System: SAMe helps produce and regulate hormones and maintain cell membranes. The enzyme SAMe synthetase is found in the liver and is the rate-limiting step for SAMe synthesis in the face of hepatic compromise. SAMe is central to hepatic methionine metabolism, glutathione synthesis, and phospholipid production.
• Cardiovascular / Homocysteine Metabolism: AdoMet is metabolized to S-adenosyl-l-homocysteine (AdoHcy) in methylation reactions, which subsequently yields homocysteine; SAMe supplementation may influence circulating homocysteine levels.
• Epigenetics / Gene Regulation: SAMe is central to methylation, a key chemical reaction increasingly appreciated as the switch that turns genes on and off in biological processes ranging from cancer metastasis to nurture's influence on nature in shaping stress reactivity.

6. Dosage Forms and Dosages Reported in Studies

SAMe can be taken orally, through a muscular injection, or by IV. The most common commercial form is an enteric-coated oral tablet, designed to protect the molecule from gastric degradation.

• Depression trials: The daily dose of SAMe in depression trials varied from 200 to 3,200 mg.
• Osteoarthritis — long-term trial: Patients received 600 mg of SAMe daily for the first two weeks and thereafter 400 mg daily until the end of the 24-month treatment period.
• Osteoarthritis — crossover trial vs. celecoxib: 1,200 mg SAMe (600 mg twice daily) was used over each 8-week phase.
• Cholestatic liver disease: An oral dose of 400 mg increased to a maximum of 1,600 mg daily has been evaluated in chronic liver diseases.

Across indications, oral doses most commonly studied range from 400 mg to 1,600 mg daily in divided doses. Parenteral formulations at lower doses have also been used in European clinical trials. It is important to note that dose ranges vary substantially across indications and study designs.

7. Safety, Adverse Effects, and Drug Interactions

General Tolerability

Side effects of SAMe are uncommon, and when they do occur they are usually minor problems such as nausea or digestive upsets. The studies in depression reported only mild, transient, or non-clinically relevant side effects. SAMe appears to be safe and might be effective in treating depression and osteoarthritis.

Bipolar Disorder

If a person has bipolar disorder, they should not take SAMe without consulting a physician first. The supplement might increase anxiety and mania.

Immunocompromised Individuals

There is a theoretical concern about the use of SAMe by people who are immunocompromised (such as those who are HIV-positive). Immunocompromised people are at risk for Pneumocystis carinii infection, and SAMe enhances the growth of this microorganism.

Drug Interactions

Serotonergic Medications

It is possible that SAMe might interact with drugs and dietary supplements that increase levels of serotonin (a chemical produced by nerve cells), such as antidepressants, L-tryptophan, and St. John's wort. The combination could cause effects similar to a condition caused by high levels of the chemical serotonin accumulating in the body — serotonin syndrome.

Specifically documented interaction concerns include:

• Dextromethorphan: taking SAMe with this cough suppressant could increase the risk of serotonin syndrome.
• Narcotics: taking SAMe with meperidine (Demerol) or tramadol (Ultram, ConZip) could increase the risk of serotonin syndrome.
• St. John's wort: caution is advised when taking this supplement with SAMe. The combination could cause serotonin syndrome.
• Amphetamines: caution is advised when taking these drugs with SAMe. The combination could increase the risk of serotonin syndrome.

Levodopa (Parkinson's Disease Medication)

SAMe might reduce the effectiveness of levodopa (Inbrija), a medication used to treat Parkinson's disease.

Potential Augmentation of Antidepressants

Compounds like S-adenosyl-methionine (SAMe) and Bupleurum chinense may enhance the effectiveness of SSRIs and reduce depressive symptoms, though caution is still advised. The interaction is double-edged: while some research suggests potential augmentation benefit, the risk of serotonin syndrome must be considered.

Stability Considerations

The uptake of exogenous SAMe is very low (<5%) and therefore large doses are required daily. SAMe is extremely unstable at temperatures above 0°C or in the presence of moisture, both as degradation of the active ingredient and as racemization of active (SS)-(+)-SAMe into inactive (RS)-(+)-SAMe. This has practical implications for product storage and quality; enteric coating and blister packaging in stable salt form are standard measures to preserve potency.

Ongoing Research

Current studies supported by the National Center for Complementary and Integrative Health (NCCIH) are investigating the role of SAMe in nonalcoholic fatty liver disease.

References

• National Center for Complementary and Integrative Health (NCCIH). S-Adenosyl-L-Methionine (SAMe): In Depth.
• Galizia I, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. PMC. 2020.
• Limveeraprajak N, et al. Efficacy and acceptability of SAMe for depressed patients: a systematic review and meta-analysis. European Psychiatry. 2024.
• Rutjes AW, et al. S-Adenosylmethionine (SAMe) for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews. 2009.
• Rutjes AW, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. PMC (Cochrane review full text). 2009.
• Najm WI, et al. S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. PMC. 2004.
• Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. Journal of Hepatology. 2012.
• Lu SC, Mato JM. S-adenosylmethionine in Liver Health, Injury, and Cancer. Physiological Reviews. 2012.
• Bottiglieri T. S-Adenosyl-l-methionine (SAMe): from the bench to the bedside — molecular basis of a pleiotropic molecule. American Journal of Clinical Nutrition. 2002.
• Mischoulon D, et al. Dietary Supplement S-Adenosyl-l-Methionine (AdoMet) Effects on Plasma Homocysteine Levels in Healthy Human Subjects: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. PMC. 2010.
• Pérez C, et al. S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy. PMC. 2025.
• Sbodio JI, et al. The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. PMC. 2021.
• Gao Y, et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. PMC. 2020.
• NIH History. Cantoni, Giulio L. (1915-2005).
• Mayo Clinic. SAMe — Drugs & Supplements.
• MSD Manual Professional. S-Adenosyl-L-Methionine.
• Intrahepatic Cholestasis of Pregnancy: Neonatal Impact Through the Lens of Current Evidence. PMC. 2025.
• S-Adenosylmethionine — Overview. ScienceDirect Topics.
• Swain MG. Fatigue in chronic liver disease: New insights and therapeutic approaches. Liver International. 2019.
• Fetrow CW, Avula JR. Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother. 2001.